Issue 22 - The Cancer Letter

Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.

SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.

LOGIN SUBSCRIBE NOW

SEARCH DATE

SEARCH TEXT

Cancel

OK

Cancel

OK

Delete Account

Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below

Flatiron compiles rich data on the uptake of PD-1 inhibitor drugs;

Cary Gross: We need to learn to analyze real-world evidence rigorously

A nascent group of academics plans to conduct randomized trials to determine value of care

MD Anderson posts four months of positive operating margins as deficit shrinks to $43.9 million

MD Anderson settles trademark litigation with Pelotonia, Soon-Shiong

In Brief

CancerLinQ partners with FDA to study real-world use of newly approved cancer treatments

NCCN and CancerLinQ collaborating to provide evidence-based, decision-making resources to physicians

First analysis of AACR Project GENIE data is published in Cancer Discovery

National Breast Cancer Coalition partners with DNA.Land to crowdsource large-scale breast cancer genomics database

Fred & Pamela Buffett Cancer Center is dedicated in Omaha

University of Pittsburgh Cancer Institute becomes UPMC Hillman Cancer Center

Markus Müschen named to The Norman and Sadie Lee Foundation Professorship in Pediatrics at COH

Drugs & Targets

Zykadia gets first-line ALK-positive metastatic NSCLC indication

Advaxis and BMS announce collaboration focused on metastatic cervical cancer

Johns Hopkins and Eisai extend drug collaboration

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login